[go: up one dir, main page]

WO2006015263A3 - Lonidamine analogs - Google Patents

Lonidamine analogs Download PDF

Info

Publication number
WO2006015263A3
WO2006015263A3 PCT/US2005/027092 US2005027092W WO2006015263A3 WO 2006015263 A3 WO2006015263 A3 WO 2006015263A3 US 2005027092 W US2005027092 W US 2005027092W WO 2006015263 A3 WO2006015263 A3 WO 2006015263A3
Authority
WO
WIPO (PCT)
Prior art keywords
lonidamine analogs
lonidamine
analogs
bph
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/027092
Other languages
French (fr)
Other versions
WO2006015263A2 (en
Inventor
Mark Matteucci
Photon Rao
Jian-Xin Duan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Molecular Templates Inc
Original Assignee
Threshold Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Threshold Pharmaceuticals Inc filed Critical Threshold Pharmaceuticals Inc
Priority to US11/346,632 priority Critical patent/US20070043057A1/en
Priority to US11/351,347 priority patent/US20070015771A1/en
Publication of WO2006015263A2 publication Critical patent/WO2006015263A2/en
Publication of WO2006015263A3 publication Critical patent/WO2006015263A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/72—Benzo[c]thiophenes; Hydrogenated benzo[c]thiophenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Lonidamine analogs are useful in the treatment of cancer and BPH.
PCT/US2005/027092 2004-07-29 2005-07-29 Lonidamine analogs Ceased WO2006015263A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US11/346,632 US20070043057A1 (en) 2005-02-09 2006-02-01 Lonidamine analogs
US11/351,347 US20070015771A1 (en) 2004-07-29 2006-02-08 Lonidamine analogs

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
US59283304P 2004-07-29 2004-07-29
US59272304P 2004-07-29 2004-07-29
US60/592,833 2004-07-29
US60/592,723 2004-07-29
US59966604P 2004-08-05 2004-08-05
US60/599,666 2004-08-05
US64618805P 2005-01-21 2005-01-21
US60/646,188 2005-01-21
US65170505P 2005-02-09 2005-02-09
US60/651,705 2005-02-09
US66106705P 2005-03-11 2005-03-11
US60/661,067 2005-03-11
US68308705P 2005-05-19 2005-05-19
US60/683,087 2005-05-19

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/346,632 Continuation-In-Part US20070043057A1 (en) 2004-07-29 2006-02-01 Lonidamine analogs

Publications (2)

Publication Number Publication Date
WO2006015263A2 WO2006015263A2 (en) 2006-02-09
WO2006015263A3 true WO2006015263A3 (en) 2006-07-27

Family

ID=35787877

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/027092 Ceased WO2006015263A2 (en) 2004-07-29 2005-07-29 Lonidamine analogs

Country Status (2)

Country Link
TW (1) TW200612918A (en)
WO (1) WO2006015263A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9493450B2 (en) 2014-02-13 2016-11-15 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
US9493442B2 (en) 2014-02-13 2016-11-15 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7514463B2 (en) * 2004-08-20 2009-04-07 University Of Kansas Lonidamine analogues and their use in male contraception and cancer treatment
KR100894006B1 (en) 2005-03-31 2009-04-17 화이자 프로덕츠 인코포레이티드 Cyclopentapyridine and tetrahydroquinoline derivatives
PL1896040T3 (en) 2005-06-29 2012-12-31 Threshold Pharmaceuticals Inc Phosphoramidate alkylator prodrugs
BRPI0707945A2 (en) 2006-02-17 2011-05-17 Pfizer Ltd 3-deazapurine derivatives as modular of tlr7
WO2008005908A2 (en) 2006-07-07 2008-01-10 Forest Laboratories Holdings Limited Pyridoimidazole derivatives
NZ596024A (en) 2006-08-07 2013-07-26 Ironwood Pharmaceuticals Inc Indole compounds
CN101541811B (en) 2006-09-19 2014-07-09 第一三共株式会社 Pyrazolopyrimidine Derivatives
US7858645B2 (en) * 2006-11-01 2010-12-28 Hoffmann-La Roche Inc. Indazole derivatives
DE102007026341A1 (en) 2007-06-06 2008-12-11 Merck Patent Gmbh Benzoxazolonderivate
DE102007032507A1 (en) 2007-07-12 2009-04-02 Merck Patent Gmbh pyridazinone derivatives
DE102007061963A1 (en) 2007-12-21 2009-06-25 Merck Patent Gmbh pyridazinone derivatives
EP2265335A1 (en) * 2008-02-29 2010-12-29 Pfizer Inc. Indazole derivatives
DE102008019907A1 (en) 2008-04-21 2009-10-22 Merck Patent Gmbh pyridazinone derivatives
DE102008028905A1 (en) 2008-06-18 2009-12-24 Merck Patent Gmbh 3- (3-pyrimidin-2-yl-benzyl) - [1,2,4] triazolo [4,3-b] pyridazine derivatives
DE102008037790A1 (en) 2008-08-14 2010-02-18 Merck Patent Gmbh Bicyclic triazole derivatives
WO2010072295A1 (en) 2008-12-22 2010-07-01 Merck Patent Gmbh Novel polymorphic forms of 6-(1-methyl-1h-pyrazol-4-yl)-2-{3-[5-(2-morpholin-4-yl-ethoxy)-pyrimidin-2-yl]-benzyl}-2h-pyridazin-3-one dihydrogenphosphate and processes of manufacturing thereof
CN102333781B (en) 2009-02-25 2014-06-11 第一三共株式会社 Tricyclic pyrazolopyrimidine derivatives
CN103154003A (en) 2010-08-23 2013-06-12 第一三共株式会社 Free crystal of tricyclic pyrazolopyrimidine derivative
WO2012026434A1 (en) 2010-08-23 2012-03-01 第一三共株式会社 Crystal of tricyclic pyrazolopyrimidine derivative
AR084433A1 (en) 2010-12-22 2013-05-15 Ironwood Pharmaceuticals Inc FAAH INHIBITORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
CN104736202B (en) 2012-08-22 2021-09-07 康奈尔大学 Methods for Inhibiting Fascin
PH12020552066A1 (en) 2014-02-13 2022-05-11 Incyte Corp Cyclopropylamines as lsd1 inhibitors
CA3195815A1 (en) * 2014-02-20 2015-08-27 Cornell University Compounds and methods for inhibiting fascin
TWI687419B (en) 2014-07-10 2020-03-11 美商英塞特公司 Imidazopyridines and imidazopyrazines as LSD1 inhibitors
US9758523B2 (en) 2014-07-10 2017-09-12 Incyte Corporation Triazolopyridines and triazolopyrazines as LSD1 inhibitors
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
WO2016007736A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyrazines as lsd1 inhibitors
EP3626720A1 (en) 2015-04-03 2020-03-25 Incyte Corporation Heterocyclic compounds as lsd1 inhibitors
MX389824B (en) 2015-08-12 2025-03-20 Incyte Holdings Corp SALTS OF A LYSINE-SPECIFIC DIMETHYLASE 1 INHIBITOR (LSD1).
US20190016680A1 (en) * 2016-01-14 2019-01-17 Beth Israel Deaconess Medical Center, Inc. Mast-cell modulators and uses thereof
WO2017121693A1 (en) 2016-01-15 2017-07-20 Bayer Pharma Aktiengesellschaft Substituted thiazole and thiadiazole amides, and use thereof
IL262488B (en) 2016-04-22 2022-08-01 Incyte Corp Formulations of an lsd1 inhibitor
EP3564214B1 (en) 2018-05-04 2024-07-03 Universita' Degli Studi G. D'annunzio Chieti - Pescara Indazole derivatives as modulators of the cannabinoid system
US10968200B2 (en) 2018-08-31 2021-04-06 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same
SG11202103131UA (en) 2018-09-28 2021-04-29 Acucela Inc Inhibitors of vap-1
WO2020069330A2 (en) * 2018-09-28 2020-04-02 Acucela Inc. Inhibitors of vap-1
KR102241064B1 (en) * 2019-07-30 2021-04-16 부산대학교 산학협력단 Novel indole derivatives and composition for preventing or treating inflammatory diseases comprising the same
EP4213839A4 (en) * 2020-09-17 2024-08-07 Escient Pharmaceuticals, Inc. Modulators of mas-related g-protein receptor x4 and related products and methods
WO2024109642A1 (en) * 2023-07-28 2024-05-30 常州大学 USE OF BENZOAZACYCLIC COMPOUND AS ALLOSTERIC MODULATOR OF β2-ADRENOCEPTOR

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHENG C.Y. ET AL.: "Indazole carboxylic acids in male contraception", CONTRACEPTION, vol. 65, no. 4, 2002, pages 265 - 268, XP003001053 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9493450B2 (en) 2014-02-13 2016-11-15 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
US9493442B2 (en) 2014-02-13 2016-11-15 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors

Also Published As

Publication number Publication date
WO2006015263A2 (en) 2006-02-09
TW200612918A (en) 2006-05-01

Similar Documents

Publication Publication Date Title
WO2006015263A3 (en) Lonidamine analogs
EP1835929B8 (en) Anti-kir combination treatments and methods
EP1587837A3 (en) Prostate cancer diagnosis and treatment
AU2003213144A1 (en) Alkylating agent combinations in the treatment of cancer
IL178012A0 (en) Diphenyl-indol-2-on compounds and their use in the treatment of cancer
ZA200409492B (en) Compositions and methods for the diagnosis and treatment of tumor.
AU2003212634A1 (en) Compounds useful in the treatment of cancer
IL180138A0 (en) 2,4,6-trisubstituted pyrimidines as phosphotidylinol (pi) 3-kinase inhibitors and their use in the treatment of cancer
WO2006113483A3 (en) Methods and compositions for treating or preventing cancer
WO2005003154A8 (en) Compositions and methods for the diagnosis and treatment of tumor
AP2005003362A0 (en) Formulation and methods for the treatment of thrombocythemia.
AU2003237792A1 (en) Compositions and methods for the diagnosis and treatment of tumor
AU2003219160A1 (en) Methods and compositions for the treatment of cancer
ZA200709542B (en) Combination therapy in the treatment of cancer
AU2003223538A1 (en) Methods for the treatment of cancer
AU2006251169A8 (en) Tetrahydropyridothiophenes for use in the treatment of cancer
AU2006251167A8 (en) Tetrahydropyridothiophenes for use in the treatment of cancer
WO2006015191A3 (en) Multicyclic lonidamine analogs
WO2007076320A8 (en) Compounds
EG24959A (en) Indoles useful in the treatment of androgenreceptor related diseases.
AU2004281077A1 (en) Methods and agents for the treatment of cancer
AU2003231803A1 (en) Treatment of cancer with mefloquire
WO2005052191A8 (en) Compositions and methods for the diagnosis and treatment of tumor
AU2003219664A1 (en) Methods and therapeutic compositions in the treatment of advanced cancer
EP1797430A4 (en) Methods and compositions for the diagnosis and treatment of cancer

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 11346632

Country of ref document: US

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWP Wipo information: published in national office

Ref document number: 11346632

Country of ref document: US

122 Ep: pct application non-entry in european phase